MOMIPP
Based on 1 Customer Validation
MOMIPP, a macropinocytosis inducer, is a PIKfyve inhibitor. MOMIPP penetrates the blood-brain barrier (BBB).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.00%
- CAS 番号: 1363421-46-8
- 分子式: C18H16N2O2
- 分子量:292.33
-
保管条件:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
生物活性
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A-375 | IC50 |
5.02 μM
Compound: 1; MOMIPP
|
Antiproliferative activity against human A375 cells after 48 hrs by MTS assay
Antiproliferative activity against human A375 cells after 48 hrs by MTS assay
|
[PMID: 29878764] |
| A549 | IC50 |
>10 μM
Compound: 1; MOMIPP
|
Antiproliferative activity against human A549 cells after 48 hrs by MTS assay
Antiproliferative activity against human A549 cells after 48 hrs by MTS assay
|
[PMID: 29878764] |
| BGC-823 | IC50 |
>10 μM
Compound: 1; MOMIPP
|
Antiproliferative activity against human BGC823 cells after 48 hrs by MTS assay
Antiproliferative activity against human BGC823 cells after 48 hrs by MTS assay
|
[PMID: 29878764] |
| HCC1806 | IC50 |
>10 μM
Compound: 1a; MOMIPP
|
Antiproliferative activity against human HCC1806 cells assessed as inhibition of cell proliferation incubated for 24 hrs by SRB assay
Antiproliferative activity against human HCC1806 cells assessed as inhibition of cell proliferation incubated for 24 hrs by SRB assay
|
[PMID: 37212861] |
| HCT-116 | IC50 |
>10 μM
Compound: 1; MOMIPP
|
Antiproliferative activity against human HCT116 cells after 48 hrs by MTS assay
Antiproliferative activity against human HCT116 cells after 48 hrs by MTS assay
|
[PMID: 29878764] |
| HeLa | IC50 |
1.22 μM
Compound: MOMIPP
|
Antiproliferative activity against human HeLa cells assessed as inhibition of cell viability incubated for 24 hrs by CCK8 assay
Antiproliferative activity against human HeLa cells assessed as inhibition of cell viability incubated for 24 hrs by CCK8 assay
|
[PMID: 38117948] |
| HepG2 | IC50 |
>10 μM
Compound: 1; MOMIPP
|
Antiproliferative activity against human HepG2 cells after 48 hrs by MTS assay
Antiproliferative activity against human HepG2 cells after 48 hrs by MTS assay
|
[PMID: 29878764] |
| MCF-10A | IC50 |
>10 μM
Compound: 1; MOMIPP
|
Cytotoxicity against human MCF10A cells assessed as reduction in cell viability after 48 hrs by MTS assay
Cytotoxicity against human MCF10A cells assessed as reduction in cell viability after 48 hrs by MTS assay
|
[PMID: 29878764] |
| MCF7 | IC50 |
>10 μM
Compound: 1; MOMIPP
|
Antiproliferative activity against human MCF7 cells after 48 hrs by MTS assay
Antiproliferative activity against human MCF7 cells after 48 hrs by MTS assay
|
[PMID: 29878764] |
| MDA-MB-231 | IC50 |
>10 μM
Compound: 1; MOMIPP
|
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTS assay
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTS assay
|
[PMID: 29878764] |
| MDA-MB-231 | IC50 |
0.88 μM
Compound: MOMIPP
|
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 24 hrs by CCK8 assay
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 24 hrs by CCK8 assay
|
[PMID: 38117948] |
| MDA-MB-435S | IC50 |
>10 μM
Compound: 1; MOMIPP
|
Antiproliferative activity against human MDA-MB-435S cells after 48 hrs by MTS assay
Antiproliferative activity against human MDA-MB-435S cells after 48 hrs by MTS assay
|
[PMID: 29878764] |
| SK-MEL-28 | IC50 |
8.156 μM
Compound: 1; MOMIPP
|
Antiproliferative activity against human SK-MEL-28 cells after 48 hrs by MTS assay
Antiproliferative activity against human SK-MEL-28 cells after 48 hrs by MTS assay
|
[PMID: 29878764] |
| SK-MEL-30 | IC50 |
>10 μM
Compound: 1; MOMIPP
|
Antiproliferative activity against human SK-MEL-30 cells after 48 hrs by MTS assay
Antiproliferative activity against human SK-MEL-30 cells after 48 hrs by MTS assay
|
[PMID: 29878764] |
| U-251 | GI50 |
2.1 μM
Compound: 1, MOMIPP
|
Growth inhibition of human U251 cells preincubated for 24 hrs followed by compound-washout measured at 48 hrs by sulforhodamine assay
Growth inhibition of human U251 cells preincubated for 24 hrs followed by compound-washout measured at 48 hrs by sulforhodamine assay
|
[PMID: 24527179] |
| U-251 | GI50 |
2.3 μM
Compound: 1a
|
Induction of methuosis in human U251 cells after 4 to 48 hrs by phase contrast microscopic analysis
Induction of methuosis in human U251 cells after 4 to 48 hrs by phase contrast microscopic analysis
|
[PMID: 27343855] |
| U-251 | GI50 |
2.32 μM
Compound: 1a
|
Growth inhibition of human U251 cells after 48 hrs by sulforhodamine B colorimetric assay
Growth inhibition of human U251 cells after 48 hrs by sulforhodamine B colorimetric assay
|
[PMID: 27343855] |
| U-251 | GI50 |
2.32 μM
Compound: 1a, MOMIPP
|
Growth inhibition of human U251 cells after 24 hrs sulphorhodomine B colorimetric assay
Growth inhibition of human U251 cells after 24 hrs sulphorhodomine B colorimetric assay
|
[PMID: 25654321] |
| U-251 | IC50 |
1.9 μM
Compound: 19, MOMIPP
|
Cytotoxicity against human U251 cells after 24 hrs by MTT assay
Cytotoxicity against human U251 cells after 24 hrs by MTT assay
|
[PMID: 22335538] |
MOMIPP can induce intense macropinocytosis, leading to methuosis in cultured glioblastoma cells at low micromolar concentrations[1].
In U373 and Hs683 cell lines, 3 μM for MOMIPP induces cell vacuolization[1].
MOMIPP (10 μM) causes early disruptions of glucose uptake and glycolytic metabolism. MOMIPP selectively activates the JNK1/2 stress kinase pathway, resulting in phosphorylation of c-Jun, Bcl-2 and Bcl-xL[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:U251 cells
-
Concentration:10 μM
-
Incubation Time:4 h or 24 h
-
Result:Activated the JNK stress kinase pathway.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Athymic CrTac:NCR-Foxn1
mice (female, 7-8 weeks)[2] -
Dosage:80 mg/kg
-
Administration:i.p.; once daily; for 15 consecutive days
-
Result:Suppressed progression of intracerebral glioblastoma xenografts.
化学情報
-
CAS 番号 1363421-46-8
-
性状 Solid
-
分子量 292.33
-
分子式 C18H16N2O2
-
Color Yellow to orange
-
SMILES
O=C(/C=C/C1=C(NC2=C1C=C(C=C2)OC)C)C3=CC=NC=C3
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
溶剤 & 溶解度
DMSO : 31.25 mg/mL (106.90 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (274 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Margaux Colin, et al. Dysregulation of Macropinocytosis Processes in Glioblastomas May Be Exploited to Increase Intracellular Anti-Cancer Drug Levels: The Example of Temozolomide. Cancers (Basel). 2019 Mar 22;11(3):411. [Content Brief]
[2]. Zehui Li, et al. The JNK signaling pathway plays a key role in methuosis (non-apoptotic cell death) induced by MOMIPP in glioblastoma. BMC Cancer. 2019 Jan 16;19(1):77. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.4208 mL | 17.1040 mL | 34.2079 mL | 85.5198 mL |
| 5 mM | 0.6842 mL | 3.4208 mL | 6.8416 mL | 17.1040 mL | |
| 10 mM | 0.3421 mL | 1.7104 mL | 3.4208 mL | 8.5520 mL | |
| 15 mM | 0.2281 mL | 1.1403 mL | 2.2805 mL | 5.7013 mL | |
| 20 mM | 0.1710 mL | 0.8552 mL | 1.7104 mL | 4.2760 mL | |
| 25 mM | 0.1368 mL | 0.6842 mL | 1.3683 mL | 3.4208 mL | |
| 30 mM | 0.1140 mL | 0.5701 mL | 1.1403 mL | 2.8507 mL | |
| 40 mM | 0.0855 mL | 0.4276 mL | 0.8552 mL | 2.1380 mL | |
| 50 mM | 0.0684 mL | 0.3421 mL | 0.6842 mL | 1.7104 mL | |
| 60 mM | 0.0570 mL | 0.2851 mL | 0.5701 mL | 1.4253 mL | |
| 80 mM | 0.0428 mL | 0.2138 mL | 0.4276 mL | 1.0690 mL | |
| 100 mM | 0.0342 mL | 0.1710 mL | 0.3421 mL | 0.8552 mL |